Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (11130)	6/7/2017 5:34:46 PM
From: tuck	Read Replies (2) \| Respond to of 12215

MGL-3196 is also supposed to be liver-specific. Makes me wonder about IP issues. FWIW, here's a short article that contains MGL-3196's discovery history & chemical structure: MGL-3196 structure VK2809 is the former MB07811 (I presume my CVR from the Metabasis munch would get a chunk per the LGND/Viking license agreement, should it ever get to market); you knew that, right MZ? Structure is one here: Targeting thyroid hormone receptor-ß agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index I'm no chemist, but the structures appear different enough to give each company room to operate. Viking saw the same effects of liver enzyme elevation at higher doses and changes in the thyroid axis. They don't specify what those higher doses were, but I'm guessing the 20mg/kg and 40mg/kg. Today's announcement suggests the 5 and 10 mg/kg doses might avoid that issue raised in the review article I cited, as you note. Interesting race, here. One thing that caught my eye . . . there are two isoforms of THR-beta. Aside from seeing their existence mentioned a couple of times, I can find nothing elucidating their differences, or any reference to these agonists preferentially activating one or the other. Cheers, Tuck